Loading
IARC estimates 3,328 new cancer cases and 1,632 cancer deaths in Montenegro in 2024; the commonest new cancers are breast, trachea, bronchus and lung and colorectum. This page is assembled automatically from OnCo's data, and says what OnCo does not yet hold.
Built partly from other countries' data. IARC's method code for Montenegro's incidence estimate is 3b: national mortality estimates applied to model-based mortality-to-incidence ratios (neighbouring country registry data). Read the figures as a regional estimate, not a count.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Breast | 493 | 83.3 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Trachea, bronchus and lung | 421 | 33.7 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Colorectum | 335 | 27.4 | Colorectal cancer |
| Prostate | 172 | 27.9 | Prostate cancer |
| Bladder | 150 | 11.6 | Bladder & urothelial cancer |
| Melanoma of skin | 117 | 10.9 | Melanoma |
| Corpus uteri | 116 | 19.2 | Endometrial cancer |
| Non-Hodgkin lymphoma | 83 | 7.4 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Pancreas | 77 | 5.8 | Pancreatic ductal adenocarcinoma |
| Thyroid | 77 | 8.1 | Thyroid cancer |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Trachea, bronchus and lung | 367 | 28.4 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Breast | 166 | 21.8 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Colorectum | 165 | 11.8 | Colorectal cancer |
| Prostate | 85 | 12.6 | Prostate cancer |
| Brain, central nervous system | 68 | 5.5 | Glioma & glioblastoma |
| Pancreas | 65 | 4.6 | Pancreatic ductal adenocarcinoma |
| Liver and intrahepatic bile ducts | 63 | 4.3 | Hepatocellular carcinoma |
| Bladder | 52 | 3.3 | Bladder & urothelial cancer |
| Stomach | 45 | 3.4 | Gastric & gastro-oesophageal junction cancer |
| Leukaemia | 38 | 2.8 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
No trial record in OnCo lists a site in Montenegro. OnCo reads sites from ClinicalTrials.gov; studies registered only elsewhere are searchable through the WHO International Clinical Trials Registry Platform.
OnCo holds no institution, company or person in Montenegro.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Montenegro is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
Montenegro is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.